Yongmei Yin

6.9k total citations · 1 hit paper
200 papers, 3.5k citations indexed

About

Yongmei Yin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yongmei Yin has authored 200 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Oncology, 71 papers in Molecular Biology and 66 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yongmei Yin's work include HER2/EGFR in Cancer Research (44 papers), Advanced Breast Cancer Therapies (35 papers) and Cancer Treatment and Pharmacology (27 papers). Yongmei Yin is often cited by papers focused on HER2/EGFR in Cancer Research (44 papers), Advanced Breast Cancer Therapies (35 papers) and Cancer Treatment and Pharmacology (27 papers). Yongmei Yin collaborates with scholars based in China, United States and Germany. Yongmei Yin's co-authors include Ziyi Fu, Lingxiang Liu, Zhaoxia Wang, Pei Hao, Chunxiao Sun, Xiang Huang, Xiaofeng Chen, Fan Yang, Tianyu Zeng and Binbin Lu and has published in prestigious journals such as Journal of the American Chemical Society, Nature Medicine and Nature Communications.

In The Last Decade

Yongmei Yin

184 papers receiving 3.5k citations

Hit Papers

Sacituzumab tirumotecan in previously treated metastatic ... 2025 2026 2025 5 10 15
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
    2025 16 citations Yongmei Yin, Xiaojia Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongmei Yin China 32 1.7k 1.3k 1.2k 680 470 200 3.5k
Jian Huang China 28 2.3k 1.3× 1.8k 1.3× 1.3k 1.1× 445 0.7× 381 0.8× 88 3.9k
Sha Zhao China 30 1.5k 0.8× 1.4k 1.1× 745 0.6× 785 1.2× 1.2k 2.5× 97 3.4k
D. Vucicevic United States 9 1.2k 0.7× 1.8k 1.4× 981 0.8× 867 1.3× 244 0.5× 30 3.6k
Giuseppe Luigi Banna Italy 33 1.2k 0.7× 2.1k 1.6× 574 0.5× 1.3k 2.0× 380 0.8× 164 3.9k
Alexander Swarbrick Australia 39 2.1k 1.2× 1.2k 0.9× 1.0k 0.9× 1.1k 1.7× 568 1.2× 105 4.2k
Jie Hu China 32 2.2k 1.3× 989 0.7× 1.8k 1.5× 700 1.0× 585 1.2× 134 4.3k
Daniel G. Stover United States 26 1.3k 0.7× 1.5k 1.1× 783 0.7× 658 1.0× 373 0.8× 148 3.1k
Kathryn C. Arbour United States 21 1.3k 0.8× 2.5k 1.9× 747 0.6× 1.8k 2.7× 448 1.0× 53 3.8k
Jin Gu China 30 1.1k 0.6× 1.5k 1.1× 665 0.6× 552 0.8× 285 0.6× 154 3.0k
Oronzo Brunetti Italy 35 1.1k 0.6× 1.5k 1.2× 783 0.7× 525 0.8× 692 1.5× 126 3.1k

Countries citing papers authored by Yongmei Yin

Since Specialization
Citations

This map shows the geographic impact of Yongmei Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongmei Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongmei Yin more than expected).

Fields of papers citing papers by Yongmei Yin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongmei Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongmei Yin. The network helps show where Yongmei Yin may publish in the future.

Co-authorship network of co-authors of Yongmei Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Yongmei Yin. A scholar is included among the top collaborators of Yongmei Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongmei Yin. Yongmei Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
You, Dongfang, Yaqian Wu, Fang Shao, et al.. (2025). A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases. Nature Communications. 16(1). 3032–3032. 1 indexed citations
2.
3.
Chu, Jiahui, Ziyi Fu, Sujie Zhang, et al.. (2024). Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities. Acta Pharmacologica Sinica. 45(6). 1287–1304. 8 indexed citations
4.
Liu, Qian, et al.. (2024). Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer. Cancer. 130(S8). 1392–1402. 8 indexed citations
5.
6.
Huang, Xiang, Nan Jin, Chunxiao Sun, et al.. (2024). Abstract PO1-04-04: Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial. Cancer Research. 84(9_Supplement). PO1–4. 1 indexed citations
7.
Yin, Yongmei, et al.. (2024). Abstract PO3-24-05: Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer. Cancer Research. 84(9_Supplement). PO3–24. 2 indexed citations
8.
Shi, Hai, Tianyu Zeng, Jiahua Yang, et al.. (2024). Multiplex Assay of Cytokines with Tunable Detection Ranges for the Precise Diagnosis of Breast Cancer. Analytical Chemistry. 96(8). 3662–3671. 4 indexed citations
9.
Gao, Hongfei, Min Yan, Qianjun Chen, et al.. (2023). Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China. Cancers. 15(17). 4360–4360. 2 indexed citations
10.
Yin, Yongmei, Feng Zhang, Huiqing Fan, et al.. (2023). Overcoming ABCB1-mediated multidrug resistance by transcription factor BHLHE40. Neoplasia. 39. 100891–100891. 6 indexed citations
11.
12.
Yin, Yongmei, et al.. (2023). The incidence of liver abnormalities is higher in inactive hepatitis B virus carriers with influenza A infection. SHILAP Revista de lepidopterología. 1(2). 93–98.
13.
Wang, Xi, Tianyu Zeng, Fan Yang, et al.. (2021). Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study. Cancer Medicine. 10(23). 8662–8672. 14 indexed citations
14.
Ma, Li, Shude Cui, Peifen Fu, et al.. (2020). Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China. Scientific Reports. 10(1). 18132–18132. 9 indexed citations
15.
Wang, Jun, Qian Li, Yongmei Yin, et al.. (2020). Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19. Frontiers in Immunology. 11. 2063–2063. 189 indexed citations
16.
Ding, Xiaorong, Yumei Li, Jun Li, & Yongmei Yin. (2020). OSW‐1 inhibits tumor growth and metastasis by NFATc2 on triple‐negative breast cancer. Cancer Medicine. 9(15). 5558–5569. 15 indexed citations
17.
18.
Li, Jianbin, Shusen Wang, Yongsheng Wang, et al.. (2017). Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China. The Oncologist. 22(11). 1333–1338. 35 indexed citations
19.
Xu, Yanjie, Yongfeng Shao, Xia Zhao, et al.. (2011). Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis. Journal of Cancer Research and Clinical Oncology. 137(12). 1841–1848. 23 indexed citations
20.
Liu, Lingxiang, Xiaoyan Shao, Wen Gao, et al.. (2010). The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data. Journal of Thoracic Oncology. 5(12). 1922–1932. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jian Huang Breakdown of academic impact, for papers by Sha Zhao Breakdown of academic impact, for papers by D. Vucicevic Breakdown of academic impact, for papers by Giuseppe Luigi Banna Breakdown of academic impact, for papers by Alexander Swarbrick Breakdown of academic impact, for papers by Jie Hu Breakdown of academic impact, for papers by Daniel G. Stover Breakdown of academic impact, for papers by Kathryn C. Arbour Breakdown of academic impact, for papers by Jin Gu Breakdown of academic impact, for papers by Oronzo Brunetti
Rankless by CCL
2026